| Q30378494 | "Prepandemic" immunization for novel influenza viruses, "swine flu" vaccine, Guillain-Barré syndrome, and the detection of rare severe adverse events |
| Q44710217 | 5 ways statistics can fool you--tips for practicing clinicians |
| Q43152358 | Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009–January 31, 2010 |
| Q33744268 | Adversomics: the emerging field of vaccine adverse event immunogenetics |
| Q51247855 | Algorithms for identification of Guillain-Barré Syndrome among adolescents in claims databases. |
| Q38045920 | Assessing the safety of influenza vaccination in specific populations: children and the elderly |
| Q88703997 | Assessing vaccine safety within Ontario's Universal Influenza Immunization Program, 2012-2013 to 2014-2015 |
| Q30428338 | Association between Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis |
| Q38902486 | Autoimmune reaction after anti-tetanus vaccination-description of four cases and review of the literature |
| Q37762550 | Could autoimmunity be induced by vaccination? |
| Q51849672 | Cumulative risk of Guillain-Barré syndrome among vaccinated and unvaccinated populations during the 2009 H1N1 influenza pandemic. |
| Q30393154 | Design of a robust infrastructure to monitor the safety of the pandemic A(H1N1) 2009 vaccination program in Taiwan |
| Q90197754 | Diagnosis and management of Guillain-Barré syndrome in ten steps |
| Q43700573 | Did the influenza A (H1N1) 2009 monovalent inactivated vaccines increase the risk for Guillain-Barré syndrome? |
| Q33588926 | Dispelling myths held by parents about the influenza vaccine |
| Q93488361 | Dissiper les mythes entretenus par les parents au sujet du vaccin contre l’influenza |
| Q98771438 | Do Vaccines Have a Role as a Cause of Autoimmune Neurological Syndromes? |
| Q28748161 | Economic appraisal of Ontario's Universal Influenza Immunization Program: a cost-utility analysis |
| Q30402750 | Estimating background rates of Guillain-Barré Syndrome in Ontario in order to respond to safety concerns during pandemic H1N1/09 immunization campaign |
| Q85022814 | Evaluation of Guillain-Barré Syndrome Among Recipients of Influenza Vaccine in 2000 and 2001 |
| Q34347005 | Evidence of effective delivery of the human papillomavirus (HPV) vaccine through a publicly funded, school-based program: the Ontario Grade 8 HPV Vaccine Cohort Study |
| Q33992093 | Factors associated with initiation and completion of the quadrivalent human papillomavirus vaccine series in an Ontario cohort of grade 8 girls |
| Q30404728 | Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe |
| Q37463235 | Guillain-Barre syndrome during the 2009-2010 H1N1 influenza vaccination campaign: population-based surveillance among 45 million Americans |
| Q38438386 | Guillain-Barre syndrome, influenzalike illnesses, and influenza vaccination during seasons with and without circulating A/H1N1 viruses. |
| Q34117850 | Guillain-Barré syndrome (GBS). |
| Q30415924 | Guillain-Barré syndrome after exposure to influenza |
| Q28291850 | Guillain-Barré syndrome after exposure to influenza virus |
| Q30357675 | Guillain-Barré syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccines: a multinational self-controlled case series in Europe |
| Q30374886 | Guillain-Barré syndrome and influenza vaccines: A meta-analysis. |
| Q34640979 | Guillain-Barré syndrome incidence in a large United States cohort (2000-2009). |
| Q30403959 | Guillain-barré syndrome following influenza vaccination: causal or coincidental? |
| Q24276196 | Guillain–Barré Syndrome—A Classical Autoimmune Disease Triggered by Infection or Vaccination |
| Q22251433 | Guillain–Barré syndrome and Fisher syndrome: Case definitions and guidelines for collection, analysis, and presentation of immunization safety data |
| Q92510854 | Gulllain-Barre Syndrome After Trivalent Influenza Vaccination in Adults |
| Q42344060 | Health care workers must protect patients from influenza by taking the annual vaccine |
| Q30411868 | Influenza vaccination coverage rate in children: reasons for a failure and how to go forward |
| Q30354181 | Influenza vaccination in India: position paper of Indian Academy of Pediatrics, 2013. |
| Q57540054 | Influenza vaccine, Guillain–Barré syndrome, and chasing zero |
| Q30385118 | Influenza vaccines: from surveillance through production to protection. |
| Q30423370 | Influenza-associated neurological complications |
| Q45873093 | Lack of association of Guillain-Barré syndrome with vaccinations |
| Q56791521 | Low reactogenicity of the virosomal subunit influenza vaccine in healthy children without risk factors |
| Q30383245 | Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project. |
| Q57101873 | Neurologic adverse events following influenza A (H1N1) vaccinations in children |
| Q30407561 | No evidence of a link between influenza vaccines and Guillain-Barre syndrome-associated antiganglioside antibodies |
| Q48274084 | Observational safety study of specific outcomes after trivalent cell culture seasonal influenza vaccination (Optaflu® ) among adults in THIN database of electronic UK primary healthcare records |
| Q34499848 | Ontology-based combinatorial comparative analysis of adverse events associated with killed and live influenza vaccines |
| Q44215384 | Patterns of emergency room visits, admissions and death following recommended pediatric vaccinations - a population based study of 969,519 vaccination events |
| Q30713580 | Post-licensure rapid immunization safety monitoring program (PRISM) data characterization |
| Q45593649 | Posterior reversible encephalopathy syndrome following measles vaccination |
| Q24646377 | Reduced reaction frequencies with repeated inactivated or live-attenuated influenza vaccination |
| Q41273106 | Relationship between Guillain-Barré syndrome, influenza-related hospitalizations, and influenza vaccine coverage |
| Q36902462 | Risk of Guillain-Barré syndrome after 2010-2011 influenza vaccination |
| Q43823253 | Risk of Guillain-Barré syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study |
| Q30362413 | Risk of Guillain-Barré syndrome following pandemic influenza A(H1N1) 2009 vaccination in Germany |
| Q30425209 | Risk of presentation to hospital with epileptic seizures after vaccination with monovalent AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine (Pandemrix): self controlled case series study. |
| Q30400676 | Safety of MF-59 adjuvanted vaccine for pandemic influenza: results of the vaccination campaign in an Italian health district |
| Q30376061 | Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring. |
| Q33779792 | Should my patient with inflammatory bowel disease on immunosuppressive therapy be vaccinated against influenza virus? |
| Q35037338 | Simulation study of the effect of influenza and influenza vaccination on risk of acquiring Guillain-Barré syndrome |
| Q97589480 | Spread of vaccine hesitancy in France: What about YouTube™? |
| Q90082688 | Surveillance for Guillain-Barré syndrome after 2015-2016 and 2016-2017 influenza vaccination of Medicare beneficiaries |
| Q92252833 | Surveillance for Guillain-Barré syndrome after influenza vaccination among U.S. Medicare beneficiaries during the 2017-2018 season |
| Q36256314 | Technical guidelines for the application of seasonal influenza vaccine in China (2014-2015). |
| Q38185741 | The Yin-Yang arms of vaccines: disease-fighting power versus tissue-destructive inflammation |
| Q57612414 | The ethics of mandatory vaccination against influenza for health care workers |
| Q53645955 | The risk of Guillain-Barré syndrome associated with influenza A (H1N1) 2009 monovalent vaccine and 2009-2010 seasonal influenza vaccines: results from self-controlled analyses. |
| Q26773027 | The safety of influenza vaccines in children: An Institute for Vaccine Safety white paper |
| Q35687236 | Transient oculomotor palsy after influenza vaccination: short report |
| Q30389265 | Update on antivirals and vaccines for seasonal and potential pandemic use. |
| Q37919183 | Use of the self-controlled case-series method in vaccine safety studies: review and recommendations for best practice |
| Q42361533 | Vaccination and autoimmune diseases: is prevention of adverse health effects on the horizon? |
| Q34227424 | Vaccination in elite athletes |
| Q59395283 | Vaccine-preventable diseases, vaccines and Guillain-Barre’ syndrome |
| Q34977408 | Vaccines and Guillain-Barré syndrome |